Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Fibrosis, and Corneal Dystrophy Therapeutics.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TGFBI/BIGH3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TGFBI/BIGH3 Recombinant Protein (Wild-Type & Mutants) HEK293 Expressed (Native Glycosylation), High Purity (>95%), Endotoxin Controlled, Sequence Verified. |
View TGFBI Products |
| Gene Delivery | TGFBI Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and overexpression assays. |
View TGFBI Products |
| Benchmark Ab | Anti-TGFBI Recombinant Antibody Sequence-verified positive control for functional blocking and binding assays. |
View TGFBI Products |
| Validator | TGFBI siRNA Set Validated knockdown sequences for target specificity verification. |
View TGFBI Products |
| Related Target A | TGFB1 Upstream inducer of TGFBI expression; crucial for mapping the TGF-beta signaling axis. |
View TGFB1 Products |
| Related Target B | ITGAV Integrin alpha-V; primary cell-surface receptor mediating TGFBI-induced migration and adhesion. |
View ITGAV Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Reconstituting Native ECM Interactions | HEK293 host expression preserves critical post-translational modifications (PTMs) and native folding of FAS1 domains. |
| Mutant Specificity in Corneal Dystrophies | Custom-designed point-mutation proteins (e.g., R124H, R555W) with verified theoretical MW and high-purity profiles. |
| Lack of Validated Control Reagents | Sequence-defined clinical benchmark antibodies included to establish baseline validation parameters. |
| Off-Target Binding & False Positives | High-specificity siRNA validation sets to confirm target-dependent phenotypes in phenotypic screens. |
Live TGFBI/BIGH3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of TGFBI (Transforming Growth Factor-Beta-Induced Protein, also known as BIGH3) is emerging as a high-potential strategy across oncology, ophthalmology, and fibrotic diseases. As an extracellular matrix (ECM) glycoprotein induced by TGF-beta, TGFBI acts as a molecular bridge, interacting with integrins (such as alpha-v beta-3 and alpha-3 beta-1) and collagens to modulate cell adhesion, migration, and survival.
In oncology, the race is intensifying to develop neutralizing monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs) that target the stromal-promoting microenvironment created by TGFBI in solid tumors (e.g., ovarian, pancreatic, and colorectal cancers). Concurrently, ophthalmology pipelines are focusing on gene therapies and siRNA-based interventions to downregulate mutant TGFBI accumulation, which causes corneal dystrophies. The next wave of R&D is directed toward breaking tumor-stroma crosstalk and preventing pathological ECM remodeling.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Neutralizing Monoclonal Antibodies | Biotech Startups, Academic Institutes | Solid Tumors (Ovarian, Pancreatic), Fibrosis | Integrin-blocking assays (Requires high-purity, native-glycosylated TGFBI protein to mimic ECM binding). |
| siRNA / Gene Therapy | Ophthalmic Biotech Companies | TGFBI-linked Corneal Dystrophies | In vitro knockdown verification (Requires sequence-verified siRNA sets and high-expression lentiviruses). |
| Small Molecule Inhibitors | Global Pharma, Oncology Consortia | Metastatic Cancer, Chemoresistance | High-throughput binding screens (Requires stable, batch-consistent mutant and wild-type recombinant proteins). |